London, UK 16 June 2023 — GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for momelotinib by three months to provide time to review recently…Original Article
GSK Announces Extension of FDA Review Period for Momelotinib
